Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])

Inclusion Criteria

• •Patients with recurrent solid tumors
• •Patients with malignant melanoma
• •Patients with hematological malignancies.
• •* Chronic myelogenous leukemia in chronic or accelerated phase, to include chronic myelomonocytic leukemia (juvenile chronic myelogenous leukemia (JCML) or CMML).
• •* Acute lymphoblastic leukemia (ALL)
• •* First remission high-risk ALL (Ph+ with initial high white blood cell (WBC)t (4-11) in infants less than 1 year and CALLA negative)
• •* Second or subsequent remission ALL or isolated extramedullary disease on or off therapy.
• •* Acute non-lymphocytic leukemia (ANLL)
• •* Patients with ANLL in first remission who have a matched sibling donor.
• •* ANLL in second remission, or patients who only achieve an initial partial remission \< 15% blasts, or early relapse.
• •* Myelodysplastic syndromes (MDS): refractory anemia (RA), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T) and CMML/JCML.
• •Selected immunodeficiencies:
• •* Wiskott-Aldrich syndrome.
• •* Severe combined immunodeficiency variants that require ablation.
• •* Hyper-Immunoglobulin M (IgM) syndrome.
• •* Other immune deficiencies after approval from the medical director.
• •Bone marrow failure syndromes (single or multiple hematopoietic lines)
• •Venous access: A double lumen central vascular access device or its equivalent will be required for all patients entered on the protocol.
• •Informed consent: The donor and the patient and/or the patient's legally authorized guardian must acknowledge in writing that consent to become a study subject has been obtained in accordance with the institutional policy approved by the United States (U.S.) Department of Health and Human Services.
• •Patient organ function requirements:
• •* Adequate renal function: serum creatinine \< 2 x normal, or creatinine clearance calculated by Schwartz formula, of glomerular filtration rate (GFR) \> 40 ml/min/1.73m2, or an equivalent GFR as determined by the institutional normal range.
• •* Adequate liver function: total bilirubin \</= 2 x normal; and Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \</= 4 x normal.
• •* Adequate cardiac function: shortening fraction of \> 24% by echocardiogram, or ejection fraction of \> 30% by radionuclide angiogram.
• •* Adequate pulmonary function: Diffusion Lung Capacity Carbon Monoxide (DLCO), Forced Expiratory Volume in 1 second (FEV1) / Forced Vital Capacity (FVC) \> 30% by pulmonary function test. For children who are uncooperative for pulmonary function tests and have no evidence of dyspnea at rest or exercise intolerance, pulse oximetry \> 94% on room air is considered acceptable.
• •* Performance status: Lansky Score \>/= 60% for children \</= 16 years of age; or Karnofsky \> 60% status for those \> 16 years of age.